134865-74-0
134865-74-0 結(jié)構(gòu)式
基本信息
4-P-PDOT
4-PHENYL-2-PROPIONAMIDOTETRALIN
N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
N-(4-Phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propionamide
Propanamide, N-(1,2,3,4-tetrahydro-4-phenyl-2-naphthalenyl)-
4-P-PDOT
4PPDOT
4P-PDOT
AH-024
4-PHENYL-2- PROPIONAMIDOTETRALIN.
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見問(wèn)題列表
MT2 receptor
In CHO-mt1 cells the amidotetraline 4-P-PDOT (10 mM) has no effect on forskolin-stimulated cyclic AMP levels, either alone, or in the presence of Melatonin. In contrast, in CHO-MT2 cells, 4-P-PDOT is an agonist, producing a concentration-dependent inhibition of forskolin stimulated cyclic AMP, with a pEC 50 value of 8.72 and intrinsic activity of 0.86.
Cell Viability Assay
| Cell Line: | HT-29 and HeLa cells. |
| Concentration: | 30 min. |
| Incubation Time: | 50 μM. |
| Result: | Produced a negligible effect on cell viability induced by melatonin. |
4-P-PDOT (0.5-1.0 mg/kg; intravenous injection; klotho mutant mice) treatment significantly reverses antioxidant effects mediated by Melatonin. And significantly reverses the changes in the levels of these GSH-related parameters. 4-P-PDOT treatment significantly reverses the memory function of Melatonin-treated klotho mutant mice. 4-P-PDOT also counteracts Melatonin-mediated attenuation in response to the decreases in phospho-ERK expression, Nrf2 nuclear translocation, Nrf2 DNA-binding activity, and GCL mRNA expression in the hippocampi of klotho mutant mice.
| Animal Model: | Klotho mutant mice treatment with Melatonin |
| Dosage: | 0.5 mg/kg or 1.0 mg/kg |
| Administration: | Intravenous injection |
| Result: | Significantly reversed antioxidant effects mediated by Melatonin. Significantly reversed the changes in the levels of these GSH-related parameters. Significantly reversed the memory function of Melatonin-treated klotho mutant mice. |